Oncura

Hyper-CVAD: what to expect, day by day

ALL (Acute Lymphoblastic Leukemia)21-day cycle8 effects documented

A strong, multi-part regimen for acute lymphoblastic leukemia, given largely in hospital. Blood counts drop very low each cycle (expected and supported). The team gives mesna and fluids to protect your bladder from cyclophosphamide; key things to report are fever, mouth sores, nerve tingling or constipation, and any blood in the urine.

An intensive regimen for ALL: 'Part A' (cyclophosphamide + vincristine + doxorubicin + dexamethasone) alternates with 'Part B' (high-dose methotrexate + cytarabine). Very low blood counts are EXPECTED each cycle. Cyclophosphamide is given WITH mesna and fluids to protect the bladder. Watch fever/infection, mouth sores, nerve effects, and bladder symptoms.

Get help straight away — this is true on any regimen, on any day.

A temperature of 100.4°F (38°C) or higher during treatment can mean a serious infection while your blood counts are low. Call your team or go to the ER — do not wait it out.

Also urgent: trouble breathing or chest pain · swelling of the face, lips or throat · new confusion or fainting · shaking chills · not being able to keep fluids down.

This is standing guidance shown to everyone. Nothing on this page is based on anything about you, and nobody is monitoring you.

One of the 8 entries below is marked provisional. They are shown because leaving them out would be its own distortion, but they have not yet been checked against the source document by a person, and they are not presented as authoritative. Every provisional entry is labelled where it appears.

Timed to the cycle

Day 1 is the day of your infusion. These are the effects a retrievable document ties to a day range for this regimen — not a prediction about you.

Very low blood counts (expected)

Typically around days 8–21

Deep drops in blood counts are expected with each intensive cycle and are managed with transfusions, growth factors, and close monitoring.

reported by about ~100% (expected) of people; severe in ~100% · Timing from the manufacturer’s prescribing information · from Cyclophosphamide, Doxorubicin

Hair loss

Typically around days 21–42

Hair loss is near-universal and grows back after treatment ends.

reported by about ~92% of people · Timing from a drug-monograph reference · from Doxorubicin, Cyclophosphamide, Vincristine

Not tied to a cycle day

These build with the number of doses, or are measured from when treatment started, so a cycle day would be the wrong shape for them. Each keeps the timing its own source states.

Fever and infection

Because counts drop very low, infections are common and often need hospital treatment (about half of patients are hospitalized for fever/infection during the course). Any fever is treated urgently.

Call your team urgently: Any fever, chills, or feeling suddenly unwell — tell staff immediately.

reported by about ~54% hospitalized for fever/infection (pneumonia ~16%, sepsis ~11%) of people · from Cyclophosphamide, Doxorubicin

Peripheral neuropathy (cumulative)

builds over cycles; often improves but may persist

Vincristine can cause numbness, tingling, or weakness in the hands and feet, and can slow the bowel (constipation, rarely a blockage). It builds with repeated doses; use the bowel routine your team recommends and report new numbness.

Call your team: Numbness that makes it hard to button clothes or walk, or no bowel movement for 3 days with belly pain.

reported by about common with cumulative dosing% of people · from Vincristine

Bladder irritation / bleeding (hemorrhagic cystitis)

during/after cyclophosphamide dosing

Cyclophosphamide can irritate the bladder lining and cause bleeding — which is why you're given mesna and extra fluids to protect it. Report burning with urination or any blood in the urine.

Call your team: Blood in the urine, or inability to pass urine.

reported by about dose-dependent; largely prevented by mesna% of people · from Cyclophosphamide

Heart-muscle weakening (cardiotoxicity)

cumulative over cycles; can be delayed years

Doxorubicin can weaken the heart's pumping, with risk rising as the total dose adds up over cycles (and higher with cyclophosphamide). Your team checks heart function; report breathlessness or swelling.

Call your team: New shortness of breath, swelling, or a rapid/irregular heartbeat.

reported by about ~3-5% CHF at ~400 mg/m² of people · from Doxorubicin

Steroid effects (dexamethasone)PROVISIONAL

during each steroid pulse

The high-dose steroid can raise blood sugar, disturb sleep, and affect mood, and adds to infection risk. Your team may monitor glucose; don't stop the steroid suddenly.

reported by about common (mood/neurologic ~4-7%)% of people · from Dexamethasone

Later risk: therapy-related MDS/AML

years after treatment

A small long-term risk of a treatment-related blood cancer (myelodysplasia/AML) years later, from the chemotherapy. Your team keeps you under long-term monitoring.

reported by about ~1% (years later) of people · from Cyclophosphamide, Doxorubicin

Where this comes from

  1. S1. Kantarjian H, hyper-CVAD in adult ALL (long-term follow-up) (2004) — PMID 15481055
  2. S2. Doxorubicin (Adriamycin) FDA label (cumulative cardiotoxicity) — FDA label
  3. S3. Vincristine sulfate FDA label (neuropathy, autonomic constipation) — FDA label
  4. S4. Cyclophosphamide FDA label (hemorrhagic cystitis; mesna; secondary MDS/AML) — FDA label

Timing windows on this page rest on:

A window appears here only where a retrievable document ties it to a drug in this regimen. Where nothing could be found, the window was removed rather than estimated — so a missing time is an honest gap, not an oversight.

Track your own cycle in Oncura →

Free, no account, nothing leaves your device.